Tianagliflozin is a selective sodium-glucose cotransporter-2 (SGLT2) inhibitor that functions as an antidiabetic agent, primarily indicated for the management of type 2 diabetes mellitus by inhibiting… Read more
Tianagliflozin is a selective sodium-glucose cotransporter-2 (SGLT2) inhibitor that functions as an antidiabetic agent, primarily indicated for the management of type 2 diabetes mellitus by inhibiting renal glucose reabsorption to promote glycosuria. This pharmaceutical category provides essential reference standards required for rigorous analytical testing, impurity profiling, and method validation during drug development. Alongside the active pharmaceutical ingredient, the inclusion of stable isotope labelled compounds like Tianagliflozin-d5 supports the development of precise quantitative bioanalytical methods. These labelled internal standards are critical for pharmaceutical laboratories when performing mass spectrometry-based assays, ensuring high accuracy and reliability in quality control processes. By utilizing these high-quality reference materials, researchers and analysts can effectively monitor compound stability and compliance with regulatory standards throughout the lifecycle of the drug product.